Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
42.15
-0.11 (-0.26%)
At close: Feb 13, 2026
SHA:603590 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 870.34 | 824.43 | 917.75 | 851.05 | 693.03 | 808.64 |
Other Revenue | 0.97 | 0.97 | 2.26 | 15.68 | 116.76 | - |
| 871.31 | 825.4 | 920.01 | 866.73 | 809.78 | 808.64 | |
Revenue Growth (YoY) | 2.96% | -10.28% | 6.15% | 7.03% | 0.14% | -24.14% |
Cost of Revenue | 85.71 | 86.26 | 101.05 | 126.65 | 105.76 | 59.25 |
Gross Profit | 785.59 | 739.14 | 818.96 | 740.07 | 704.02 | 749.4 |
Selling, General & Admin | 567.88 | 553.76 | 583.28 | 525.88 | 479.34 | 535.52 |
Research & Development | 52.7 | 54.94 | 94.91 | 86.78 | 102.27 | 93.11 |
Other Operating Expenses | 8.38 | 6.75 | 5.64 | 6.04 | 8.69 | 11.82 |
Operating Expenses | 643.9 | 620.37 | 689.42 | 620.56 | 591.51 | 637.72 |
Operating Income | 141.69 | 118.77 | 129.54 | 119.51 | 112.51 | 111.67 |
Interest Expense | -7.18 | -6.16 | -2.78 | -0.86 | -1.41 | -0.42 |
Interest & Investment Income | 25.94 | 30.98 | 19.33 | 18.52 | 24.57 | 59.96 |
Currency Exchange Gain (Loss) | -1.29 | -1.29 | 0.5 | 0.26 | 0.31 | -0 |
Other Non Operating Income (Expenses) | -13.75 | -1.56 | -1.7 | -0.36 | 1.58 | -2.04 |
EBT Excluding Unusual Items | 145.4 | 140.74 | 144.9 | 137.06 | 137.57 | 169.17 |
Impairment of Goodwill | -97.64 | -97.64 | - | - | - | - |
Gain (Loss) on Sale of Investments | -1.28 | -0.49 | -12.78 | -7.65 | 35.64 | 1.36 |
Gain (Loss) on Sale of Assets | 0.11 | -0.03 | -0.13 | -0.01 | 0 | -0.08 |
Asset Writedown | -7.77 | -7.77 | - | -4.06 | - | - |
Other Unusual Items | 4.05 | 4.05 | -9.26 | 14.98 | 15.64 | 37.57 |
Pretax Income | 42.86 | 38.86 | 122.73 | 140.32 | 188.86 | 208.02 |
Income Tax Expense | 10.55 | 17.33 | -64.84 | 16.42 | 21.42 | 24.67 |
Earnings From Continuing Operations | 32.31 | 21.53 | 187.57 | 123.89 | 167.44 | 183.35 |
Minority Interest in Earnings | 24.81 | 20.69 | -37.12 | -22.4 | -19.46 | 0 |
Net Income | 57.12 | 42.22 | 150.45 | 101.49 | 147.99 | 183.36 |
Net Income to Common | 57.12 | 42.22 | 150.45 | 101.49 | 147.99 | 183.36 |
Net Income Growth | -50.24% | -71.94% | 48.24% | -31.42% | -19.29% | -31.09% |
Shares Outstanding (Basic) | 157 | 156 | 157 | 156 | 157 | 159 |
Shares Outstanding (Diluted) | 157 | 156 | 157 | 156 | 157 | 159 |
Shares Change (YoY) | 0.03% | -0.23% | 0.37% | -0.82% | -1.26% | -0.53% |
EPS (Basic) | 0.36 | 0.27 | 0.96 | 0.65 | 0.94 | 1.15 |
EPS (Diluted) | 0.36 | 0.27 | 0.96 | 0.65 | 0.94 | 1.15 |
EPS Growth | -50.26% | -71.88% | 47.69% | -30.85% | -18.26% | -30.72% |
Free Cash Flow | 62.22 | 68.22 | 98.44 | 23.38 | -108.43 | 8.03 |
Free Cash Flow Per Share | 0.40 | 0.44 | 0.63 | 0.15 | -0.69 | 0.05 |
Dividend Per Share | 0.600 | 0.600 | 0.300 | 0.200 | 0.300 | 0.350 |
Dividend Growth | 100.00% | 100.00% | 50.00% | -33.33% | -14.29% | -30.00% |
Gross Margin | 90.16% | 89.55% | 89.02% | 85.39% | 86.94% | 92.67% |
Operating Margin | 16.26% | 14.39% | 14.08% | 13.79% | 13.89% | 13.81% |
Profit Margin | 6.56% | 5.12% | 16.35% | 11.71% | 18.27% | 22.68% |
Free Cash Flow Margin | 7.14% | 8.27% | 10.70% | 2.70% | -13.39% | 0.99% |
EBITDA | 163.77 | 146.73 | 165.35 | 151.54 | 144.29 | 141.71 |
EBITDA Margin | 18.80% | 17.78% | 17.97% | 17.48% | 17.82% | 17.52% |
D&A For EBITDA | 22.08 | 27.96 | 35.8 | 32.03 | 31.78 | 30.04 |
EBIT | 141.69 | 118.77 | 129.54 | 119.51 | 112.51 | 111.67 |
EBIT Margin | 16.26% | 14.39% | 14.08% | 13.79% | 13.89% | 13.81% |
Effective Tax Rate | 24.62% | 44.60% | - | 11.70% | 11.34% | 11.86% |
Revenue as Reported | 871.31 | 825.4 | 920.01 | 866.73 | 809.78 | 808.64 |
Advertising Expenses | - | - | - | 32.55 | 350.29 | 448.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.